natgillin/translations-raw huggingface dataset:
Mixtard 30 100 international units/ml Suspension for injection
Mixtard 30 100 internacionalnih jedinica/ml Suspenzija za injekciju
Mixtard 30 100 international units/ml suspension for injection in vial human insulin
Mixtard 30 100 internacionalnih jedinica/ml suspenzija za injekciju u bočici humani inzulin
Mixtard 30 100 international units/ml suspension for injection.
Mixtard 30 100 internacionalnih jedinica/ml suspenzija za injekciju.
Mixtard 30 40 international units/ml Suspension for injection
Mixtard 30 40 internacionalnih jedinica/ml Suspenzija za injekciju
Mixtard 30 40 international units/ml suspension for injection in vial human insulin
Mixtard 30 40 internacionalnih jedinica/ml suspenzija za injekciju u bočici humani inzulin
Mixtard 30 40 international units/ml suspension for injection.
Mixtard 30 40 internacionalnih jedinica/ml suspenzija za injekciju.
Mixtard 30 contains less than 1 mmol sodium (23 mg) per dose, i.e.
Mixtard 30 sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
Mixtard 30 FlexPen 100 international units/ml Suspension for injection
Mixtard 30 FlexPen 100 internacionalnih jedinica/ml Suspenzija za injekciju
Mixtard 30 FlexPen 100 international units/ml suspension for injection in pre-filled pen human insulin
Mixtard 30 FlexPen 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Mixtard 30 FlexPen 100 international units/ml Suspension for injection in pre-filled pen Insulin human
Mixtard 30 FlexPen 100 internacionalnih jedinica/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Mixtard 30 InnoLet 100 international units/ml Suspension for injection
Mixtard 30 InnoLet 100 internacionalnih jedinica/ml Suspenzija za injekciju
Mixtard 30 InnoLet 100 international units/ml suspension for injection in pre-filled pen human insulin
Mixtard 30 InnoLet 100 internacionalnih jedinica/ml suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Mixtard 30 InnoLet 100 international units/ml Suspension for injection in pre-filled pen Insulin human
Mixtard 30 InnoLet 100 internacionalnih jedinica/ml Suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Mixtard 30 InnoLet, Mixtard 40 and 50 Penfill:
Mixtard 30 InnoLet, Mixtard 40 i 50 Penfill:
Mixtard 30 is essentially ‘sodium- free’.
Mixtard 30 sadrži zanemarive količine natrija.
Mixtard 30 Penfill 100 international units/ml Suspension for injection
Mixtard 30 Penfill 100 internacionalnih jedinica/ml Suspenzija za injekciju
Mixtard 30 Penfill 100 international units/ml suspension for injection in cartridge human insulin
Mixtard 30 Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku humani inzulin
MIXTARD 30 suspension for injection in pre-filled pen.
MIXTARD 30 suspenzija za injekciju u napunjenoj brizgalici.
Mixtard 30 vial, Penfill and FlexPen:
Mixtard 30 bočica, Penfill i FlexPen:
Mixtard 40 contains less than 1 mmol sodium (23 mg) per dose, i.e.
Mixtard 40 sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
Mixtard 40 is essentially ‘sodium- free’.
Mixtard 40 sadrži zanemarive količine natrija.
Mixtard 40 Penfill 100 international units/ml Suspension for injection
Mixtard 40 Penfill 100 internacionalnih jedinica/ml Suspenzija za injekciju
Mixtard 40 Penfill 100 international units/ml suspension for injection in cartridge human insulin
Mixtard 40 Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku humani inzulin
Mixtard 50 contains less than 1 mmol sodium (23 mg) per dose, i.e.
Mixtard 50 sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
Mixtard 50 is essentially ‘sodium- free’.
Mixtard 50 sadrži zanemarive količine natrija.
Mixtard 50 Penfill 100 international units/ml Suspension for injection
Mixtard 50 Penfill 100 internacionalnih jedinica/ml Suspenzija za injekciju
Mixtard 50 Penfill 100 international units/ml suspension for injection in cartridge human insulin
Mixtard 50 Penfill 100 internacionalnih jedinica/ml suspenzija za injekciju u ulošku humani inzulin
Mixtard can be used in children and adolescents.
Mixtard se može primjenjivati u djece i adolescenata.
Mixtard contains less than 1 mmol sodium (23 mg) per dose, i.e.
Mixtard sadrži manje od 1 mmol (23 mg) natrija po dozi, tj.
Mixtard contains sodium
Mixtard sadrži natrij
Mixtard FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Mixtard FlexPen je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
Mixtard FlexPen is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Mixtard FlexPen priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje treba slijediti.
Mixtard InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Mixtard InnoLet je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
Mixtard InnoLet is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Mixtard InnoLet priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje treba slijediti.
Mixtard is essentially ‘sodium-free’.
Mixtard sadrži zanemarive količine natrija.
Mixtard vial is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz Mixtard bočicu priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje treba slijediti.
Mixtard vials are for use with insulin syringes with the corresponding unit scale.
Mixtard bočice koriste se s inzulinskim štrcaljkama s odgovarajućom jediničnom skalom.
ml (Fill 2.36 ml)
ml (Punjenje 2,36 ml)
mL cartridge (type I glass, with a bromobutyl rubber plunger stopper and an aluminium crimp cap with bromobutyl rubber) preassembled in a prefilled pen.
Uložak od 3 ml (staklo tip I s čepom klipa od bromobutilne gume i aluminijskim zatvaračem s brombutilnom gumom), posloženi u brizgalicu.
ml clear glass Type I vial with a bromobutyl rubber stopper and aluminium seal and a plastic flip-off cap containing 1 ml of concentrate for solution for infusion.
Prozirna staklena bočica od 6 ml (staklo tip I) s 1 ml koncentrata za otopinu za infuziju, s bromobutilnim gumenim čepom i aluminijskim prstenom te plastičnim "flip off" zatvaračem.
ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a blue flip-off aluminium over seal containing 4 ml of concentrate.
Prozirna bezbojna staklena bočica od 6 ml (staklo tip I) s 4 ml koncentrata, zatvorena gumenim (flurotec) čepom i plavim „flip-off“ aluminijskim zaštitnim zatvaračem.
ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a green flip-off aluminium over seal containing 1 ml of concentrate.
Prozirna, bezbojna staklena bočica od 6 ml (staklo tip I) s 1 ml koncentrata, zatvorena gumenim (flurotec) čepom i zelenim „flip-off“ aluminijskim zaštitnim zatvaračem.
ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a red flip-off aluminium over seal containing 6 ml of concentrate.
Prozirna bezbojna staklena bočica od 6 ml (staklo tip I) sa 6 ml koncentrata, zatvorena gumenim (flurotec) čepom i crvenim “filp-off” aluminijskim zaštitnim zatvaračem.
ml concentrate in plastic vial made of clear, colourless cycloolefine copolymer with Type I bromobutyl rubber stopper and sealed with aluminium polypropylene flip off seal.
Plastična bočica s 5 ml koncentrata izrađena od prozirnog, bezbojnog cikloolefinskog kopolimera s čepom od brombutilne gume tipa I i zatvorena aluminijskim polipropilenskim „flip-off“ poklopcem.
ml contains 100 U (approximately 0.58 mg) of laronidase.
1 ml sadrži 100 U (približno 0,58 mg) laronidaze.
ml contains 100 units (3.64 mg) insulin glargine
ml sadrži 100 jedinica (3,64 mg) inzulina glargina
ml contains:
ml sadrži:
mL of solution (corresponding to 18 MIU) is contained in a multidose vial (type I glass) with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene).
ml otopine (što odgovara 18 milijuna IU) sadržane u višedoznoj bočici (staklo tipa I), s čepom (halobutilna guma) u (aluminijskom) "flip-off" zatvaraču, s (polipropilenskim) poklopcem.
ml of solution contains 0.9 mg bromfenac (as sodium sesquihydrate).
ml otopine sadrži 0,9 mg bromfenaka (u obliku bromfenaknatrij seskvihidrata).
ml of solution contains emedastine 0.5 mg (as difumarate).
ml otopine sadržava 0,5 mg emedastina (u obliku emedastindifumarata).
ml of solution in a 3 ml pre-filled syringe (type I glass) with plunger stopper (bromobutyl coated with fluorocarbon polymer).
ml otopine u napunjenoj štrcaljki od 3 ml (staklo tipa I) s čepom klipa (bromobutil obložen polimerom fluorougljika).
ml of solution in a 5 ml vial (type I glass) closed with a stopper (bromobutyl/isoprene polymer) and a seal (lacquered plastic).
ml otopine u bočici od 5 ml (staklo tipa I) zatvorenoj čepom (polimer bromobutil/izoprena) i zaštitnim poklopcem (lakirana plastika).
ml oral solution 150 ml oral solution 480 ml oral solution
50 ml oralne otopine 150 ml oralne otopine 480 ml oralne otopine
ml product/day = Total estimated body weight (kg) of chicken to be treated x 0.005 ml Examples:
ml proizvoda/ dan = ukupno procijenjena tjelesna težina (kg) kokoši koje treba tretirati x 0,005 ml
ml product/day = Total estimated body weight (kg) of pigs to be treated x 0.0125 ml Examples:
ml proizvoda/dan = ukupno procijenjena tjelesna težina (kg) svinja koje treba tretirati x 0,0125 ml Primjeri:
ml round opaque low density polyethylene bottles with a dispensing plug and white polypropylene screw cap (DROP-TAINER) containing 5 ml suspension.
Okrugle, neprozirne bočice od polietilena niske gustoće volumena 5 ml, s nastavkom za kapanje i bijelim polipropilenskim navojnim zatvaračem (DROP-TAINER) koje sadrže 5 ml suspenzije.
ml solution contains 100 units insulin aspart (equivalent to 3.5 mg).
ml otopine sadrži 100 jedinica aspart inzulina (što odgovara 3,5 mg).
ml solution contains 100 units insulin detemir (equivalent to 14.2 mg).
ml otopine sadrži 100 jedinica detemir inzulina (što odgovara 14,2 mg).
ml solution in a cartridge (colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
ml otopine u ulošku (bezbojno staklo) s klipom (elastomerna brombutilna guma) i zatvaračem s rubnikom (aluminij) i čepom (elastomerna brombutilna guma).
ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml otopine u ulošku (bezbojno staklo tipa 1) s klipom (brombutilna guma (tipa 1)) te zatvaračem s rubnikom (aluminij) s čepom (bromobutilna guma ili poliizoprenski laminat i bromobutilna guma (tipa 1)).
ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml otopine u ulošku (bezbojno staklo tipa 1) s klipom (bromobutilna guma (tipa 1)) i zatvaračem s rubnikom (aluminij) s čepom (bromobutilna guma ili poliizoprenski laminat i bromobutilna guma (tipa 1)).
mL solution in a cartridge (type 1 colourless glass) with a plunger (chlorobutyl rubber) and a disc seal (laminate of polyisoprene and bromobutyl rubber) with aluminium seal.
ml otopine u ulošku (bezbojno staklo tipa 1) s klipom (klorbutilna guma) te čepom u obliku pločice (poliizoprenski laminat i bromobutilna guma) s aluminijskim zaštitnim zatvaračem.
mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a stopper (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polycarbonate and acrylonitrile butadiene styrene.
ml otopine u ulošku (staklo tipa 1) s klipom (halobutil) i čepom (halobutil/poliizopren) nalazi se u jednokratnoj, višedoznoj napunjenoj brizgalici od polipropilena, polikarbonata i akrilonitril butadien stirena.
ml solution in a cartridge (type I colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
ml otopine u ulošku (bezbojno staklo tipa I) s klipom (elastomerna brombutilna guma) i zatvaračem s rubnikom (aluminij) i čepom (elastomerna brombutilna guma).
ml solution in a single use Type 1 glass vial with (butyl) rubber stopper and aluminium over-seal.
ml otopine u jednokratnoj staklenoj bočici (staklo tipa 1) sa čepom od (butil)gume i aluminijskim zaštitnim zatvaračem.
ml suspension contains 1 g mycophenolate mofetil when reconstituted.
ml pripremljene suspenzije sadrži 1 g mofetilmikofenolata
ml type I glass vial, with teflon-coated, butyl rubber stopper and flip-off aluminium over seal, containing 2 ml of solution.
Bočica od 5 ml, od stakla tipa I, s čepom od butilne gume obloženim teflonom i „flip-off“ aluminijskim zaštitnim zatvaračem, koja sadrži 2 ml otopine.
ml vial (type 1 clear glass) with a stopper (chlorobutyl rubber), seal (aluminium) and a flip-off cap (polypropylene).
Bočica od 5 ml (prozirno staklo tipa 1) s čepom (klorobutilna guma), prstenom (aluminij) i flip-off kapicom (polipropilen).
ml water for injections
ml vode za injekcije
ml/hour
ml/sat
ml/min/1.73 m2
ml/min/1,73 m2
ML18147: Avastin 5.0 mg/kg of body weight every 2 weeks or Avastin 7.5 mg/kg of body weight every 3 weeks in combination with fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin in patients with disease progression following first-line treatment with bevacizumab.
ML18147: Avastin u dozi od 5,0 mg/kg tjelesne težine svaka 2 tjedna ili Avastin u dozi od 7,5 mg/kg tjelesne težine svaka 3 tjedna u kombinaciji s fluoropirimidinom/irinotekanom ili fluoropirimidinom/oksaliplatinom u bolesnika u kojih je došlo do progresije bolesti nakon liječenja bevacizumabom u prvoj liniji.
MLSB resistance may be constitutive or inducible.
MLSB otpornost može biti konstitutivna ili inducibilna.
MMF: monitoring for MPA- related toxicities is advised.
MMF: preporučuje se praćenje toksičnosti povezane s MPA.
MMR at 12 months
MMR u 12. mjesecu
MMR rates by specific timepoint are displayed graphically in Figure 2.
Stope MMR u specifičnim vremenskim točkama grafički su prikazane na Slici 2.
MMRat 12 months
MMR u 12. mjesecu
MMRd, % (95% CI)
MMRd, % (95%-tni IP)
MN = Multiples of Normal, CI = confidence interval
MN = višekratnik normalne vrijednosti, CI = interval pouzdanosti
MN Assay All subjects Seronegative subjects at baseline (< 1:10)
MN analiza Svi ispitanici Ispitanici seronegativni na početku (< 1:10)
MN results against a A/Vietnam/1194/2004 indicate a seroprotection rate of 99% (95%CI: 94-100), a seroconversion rate ranging from 97% (95%CI: 91-99) to 99% (95%CI: 96-100) and a GMR ranging from 29 (95%CI: 25-35) to 50 (95%CI: 44-58).
Rezultati MN analize na virus A/Vietnam/1194/2004 ukazuju na stopu serozaštite od 99% (95%CI: 94-100), stopa serokonverzije u rasponu od 97% (95%CI: 91-99) do 99% (95%CI: 96-100) i omjer srednjih geometrijskih vrijednosti (GMR) u rasponu od 29 (95%CI: 25-35) do 50 (95%CI: 44-58).
MN results against a A/Vietnam/1194/2004 indicate a seroprotection rate of 99% (95%CI: 94-100), a seroconversion rate ranging from 97% (95%CI: 91-99) to 99% (95%CI: 96-100) and a GMR ranging from 29 (95%CI: 25-35) to 50 (95%CI: 44-58).
Rezultati MN testiranja na virus A/Vietnam/1194/2004 ukazuju na stopu serozaštite od 99% (95%CI: 94-100), stopu serokonverzije u rasponu od 97% (95%CI): 91-99) do 99% (95%CI: 96-100) iGMR u rasponu od 29 (95%CI: 25-35) do 50 (95%CI: 44-58).
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively.
Rezultati mikroneutralizacijske analize (MN) na virus A/Vietnam/1194/2004 ukazuju na stopu serozaštite i serokonverzije u rasponu od 67% (60-74) do 85% (78-90), odnosno od 65% (58-72) do 83% (77-89).
MN results against homologous A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively.
Rezultati MN analize na homologni virus A/Vietnam/1194/2004 upućuju na stopu seroprotekcije i serokonverzije u rasponu od 67% (60-74) do 85% (78-90), odnosno od 65% (58-72) do 83% (77-89).
MN results against homologous A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from of 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69) respectively.
Rezultati MN analize na homologni virus A/Vietnam/1194/2004 upućuju na stopu seroprotekcije i serokonverzije u rasponu od 57% (50-64) do 79% (68-87), odnosno od 55% (48-62) do 58% (47-69).
MN results for A/H5N1/Indonesia/5/05 revealed a seroprotection rate of 38% (31-45) in adults (18-60 years) and 14% (8-20) in elderly (>60 years); a seroconversion rate of 58% (50-65) in adults and 30% (23-38) in elderly and finally a GMR of 4.67 (3.95-5.56) in adults and 2.19 (1.86-2.58) in elderly.
Rezultati MN analize za virus A/H5N1/Indonesia/5/05 pokazali su stopu seroprotekcije od 38% (31-45) u odraslih osoba (18-60 godina) i 14% (8-20) u starijih osoba (>60 godina): stopa serokonverzije od 58% (50-65) u odraslih osoba i 30% (23-38) u starijih osoba te omjer srednje geometrijske vrijednosti (GMR) od 4,67 (3,95-5,56) u odraslih osoba i 2,19 (1,86-2,58) u starijih osoba.
MN results for A/H5N1/Vietnam/1194/2004 revealed a seroprotection rate of 10% (6-16) in adults (18-60 years) and 6% (3-11) in elderly (>60 years); a seroconversion rate of 19% (13-25) in adults and 7% (4-13) in elderly and finally a GMR of 1.86 (1.63-2.12) in adults and 1.33 (1.17-1.51) in elderly.
Rezultati MN analize za virus A/H5N1/Vietnam/1194/2004 pokazali su stopu seroprotekcije od 10% (6-16) u odraslih osoba (18-60 godina) i 6% (3-11) u starijih osoba (>60 godina): stopu serokonverzije od 19% (13-25) u odraslih osoba i 7% (4-13) u starijih osoba te omjer srednje geometrijske vrijednosti (GMR) od 1,86 (1,63-2,12) u odraslih osoba i 1,33 (1,17-1,51) u starijih osoba.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 11% (3-25) (study V87P1) to 30% (24-37) (study V87P13) and seroconversion rate of 25% (19-31) for study V87P13.
Rezultati MN analize za klinička ispitivanja u gornjoj tablici ukazali su na stopu serozaštite od virusa A/turkey/Turkey/05 u rasponu od 11% (3-25) (studija V87P1) do 30% (24-37) (studija V87P13) te stopu serokonverzije od 25% (19-31) za studiju V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 27% (17-39) (V87P1) to 39% (32-46) (V87P13) and seroconversion rate of 36% (29-43) for V87P13 study.
Rezultati MN analize za klinička ispitivanja u gornjoj tablici ukazali su na stopu serozaštite od virusa A/turkey/Turkey/05 u rasponu od 27% (17-39) (V87P1) do 39% (32-46) (V87P13) te stopu serokonverzije od 36% (29-43) za studiju V87P13.
MN results for the three clinical studies in the Table above revealed a seroprotection rate and seroconversion rate against A/turkey/Turkey/05 ranging from 10% (2-27) to 39% (32-46) and 10% (2-27) to 36% (29-43) respectively.
Rezultati MN analize za tri klinička ispitivanja u gornjoj tablici pokazali su stopu seroprotekcije na virus A/turkey/Turkey/05 u rasponu od 10% (2-27) do 39% (32-46) te stopu serokonverzije od 10% (2-27) do 36% (29-43).
MN results in study V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.01 (1.78-2.26).
A/turkey/Turkey/05 bio 2,01 (1,78-2,26).
MN results in study V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.77 (2.4-3.2).
Rezultati MN analize u studiji V87P13 pokazali su da je omjer srednje geometrijske vrijednosti protiv virusa A/turkey/Turkey/05 bio 2,77 (2,4-3,2).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.01 (1.78-2.26).
Rezultati MN analize u studiji V87P13 pokazali su da je omjer srednje geometrijske vrijednosti (GMR) protiv virusa A/turkey/Turkey/05 bio 2,01 (1,78-2,26).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.01 (1.78-2.26).
V87P13 pokazali su da je omjer srednje geometrijske vrijednosti (GMR) protiv virusa A/turkey/Turkey/05 bio 2,01 (1,78-2,26).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.77 (2.4-3.2).
Rezultati MN analize u studiji V87P13 pokazali su da je omjer srednje geometrijske vrijednost (GMR) protiv virusa A/turkey/Turkey/05 bio 2,77 (2,4-3,2).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.77 (2.4-3.2).
Rezultati MN analize u studiji V87P13 pokazali su da je omjer srednje geometrijske vrijednosti (GMR) protiv virusa A/turkey/Turkey/05 bio 2,77 (2,4-3,2).
MN results yielded a GMR against A/turkey/Turkey/05 ranging from 1.59 to 2.95.
Rezultati MN analize pokazali su da je omjer srednjih geometrijskih vrijednosti (GMR) protiv virusa A/turkey/Turkey/05 u rasponu od 1,59 do 2,95.
MN results yielded a GMR against A/turkey/Turkey/05 ranging from 1.59 to 2.95.
Rezultati MN analize pokazali su da je srednja geometrijska vrijednost (GMR) protiv virusa A/turkey/Turkey/05 u rasponu od 1,59 do 2,95.
MN results, similar to SRH results demonstrated strong immune response after completion of priming vaccination series in a population of elderly subjects.
Rezultati MN analize, slični rezultatima SRH analize, pokazali su snažan imunološki odgovor nakon dovršetka primarnog cijepljenja u populaciji starijih ispitanika.
MN results, similar to SRH results demonstrated strong immune response after completion of priming vaccination series in a population of elderly subjects.
Rezultati MN analize, slični rezultatima SRH analize, pokazali su snažan imunološki odgovor nakon dovršetka prve serije cijepljenja u populaciji starijih ispitanika.
MN titer ≥ 20
Faktorserokonverzije
MN titer ≥ 20
MN titar ≥ 20
MN titre ≥ 1:40
MN titar ≥ 1:40
MN titre ≥ 20
MN titar ≥ 20
MN titre ≥ 20 a 21 days after 2nd dose
MN titar ≥ 20 a 21 dan nakon 2.doze
MO22224 evaluated the efficacy and safety of bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
U ispitivanju MO22224 ocijenjene su djelotvornost i sigurnost bevacizumaba u kombinaciji s paklitakselom, topotekanom ili pegiliranim liposomalnim doksorubicinomu u bolesnica s recidivom epitelnog karcinoma jajnika, karcinoma jajovoda ili primarnog peritonealnog karcinoma rezistentnih na platinu.
Mobilisation and engraftment data from supportive Phase II studies (plerixafor 0.24 mg/kg dosed on the evening or morning prior to apheresis) in patients with non-Hodgkin’s lymphoma, Hodgkin’s disease, or multiple myeloma were similar to those data for the Phase III studies.
Podaci o mobilizaciji i usađivanju iz potpornih ispitivanja faze II (pleriksafor u dozi od 0,24 mg/kg primijenjen navečer ili ujutro prije afereze) u bolesnika s ne-Hodgkinovim limfomom, Hodgkinovom bolešću ili multiplim mijelomom slični su ovim podacima iz ispitivanja faze III.
Mobilisation of PBPC
Mobilizacija progenitorskih stanica iz periferne krvi
Mobilisation of PBPC
Mobilizacija progenitorskih stanica koštane srži
Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.
Zdravi davatelj nema izravne kliničke koristi od mobilizacije progenitorskih stanica periferne krvi te o tom postupku treba razmišljati samo u svrhu alogenog presađivanja matičnih stanica.
Mobilisation of peripheral blood progenitor cells (PBPC)
Mobilizacija stanica preteča periferne krvi
Mobilisation of peripheral blood progenitor cells (PBPCs).
Mobilizacija progenitorskih stanica iz periferne krvi (PBPC-ova, engl. peripheral blood progenitor cells).
Mobilisation will be started by first giving you another medicine called G-CSF (granulocyte-colony stimulating factor).
Mobilizacija će početi nakon što prvo primite lijek koji se zove čimbenik poticanja rasta granulocita (G-CSF).
mobility decreased
poremećaji zglobova smanjena pokretljivost
Mobilization of PBPC
Mobilizacija stanica preteča koštane srži